Oruka Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Oruka Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Feb 1, 2024 |
| FY2022 | Dec 31, 2022 | $0 | Feb 24, 2023 |
| FY2021 | Dec 31, 2021 | $0 | Mar 14, 2022 |
| FY2020 | Dec 31, 2020 | $0 | Mar 18, 2021 |
| FY2019 | Dec 31, 2019 | $0 | Feb 18, 2020 |
| FY2018 | Dec 31, 2018 | $0 | Feb 27, 2019 |
| FY2017 | Dec 31, 2017 | $0 | Mar 22, 2018 |
| FY2016 | Dec 31, 2016 | $0 | Mar 21, 2017 |
| FY2015 | Dec 31, 2015 | $0 | Mar 17, 2016 |
| FY2014 | Dec 31, 2014 | $0 | Mar 19, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($105.43M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($83.72M) | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | ($5.34M) | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | ($9.93M) | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.32M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($9.74M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($5.48M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($7.93M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($18.49M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($16.44M) | Mar 22, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($122.05M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($88.12M) | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | ($7.30M) | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | ($10.60M) | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.34M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($9.77M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($5.81M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($8.12M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($18.71M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($16.61M) | Mar 22, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.64M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $75.06M | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | $1.01M | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | $4.75M | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | $13.83M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $4.99M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $1.83M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $4.24M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $14.08M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $12.35M | Mar 22, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $4.01M | Mar 20, 2014 |
| FY2013 | Dec 31, 2012 | $3.23M | Mar 20, 2014 |
| FY2012 | Dec 31, 2011 | $5.05M | Mar 21, 2013 |
| FY2011 | Dec 31, 2010 | $6.07M | Mar 27, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($88.21M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($57.84M) | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | ($5.01M) | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | ($10.91M) | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | ($18.76M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($7.73M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($4.80M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($8.24M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($17.47M) | Feb 27, 2019 |
| FY2013 | Dec 31, 2013 | ($5.29M) | Mar 20, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $189.0K | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | $0 | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | $2.0K | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | $43.0K | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $19.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $4.0K | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $4.0K | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $3.0K | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $12.0K | Mar 22, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $488.62M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $396.02M | Mar 12, 2026 |
| FY2024 | Feb 6, 2024 | $1.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2023 | $37.86M | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | $43.09M | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | $54.92M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $50.43M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $8.54M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $6.83M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $12.37M | Feb 27, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.69M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $13.80M | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | $841.0K | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | $1.41M | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.88M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $3.91M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $926.0K | Mar 18, 2021 |
| FY2018 | Dec 31, 2018 | $793.0K | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $2.09M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.44M | Mar 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $471.93M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $382.22M | Mar 12, 2026 |
| FY2025 | Feb 6, 2024 | $1.0K | Mar 12, 2026 |
| FY2024 | Feb 5, 2024 | $1.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2023 | $37.02M | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | $41.67M | Feb 1, 2024 |
| FY2023 | Dec 31, 2021 | $51.04M | Feb 1, 2024 |
| FY2022 | Dec 31, 2020 | $46.52M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $7.61M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $6.03M | Mar 18, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($189.16M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($83.72M) | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | ($188.74M) | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | ($183.40M) | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | ($173.48M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($154.15M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($144.42M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($138.93M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($131.00M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($112.51M) | Mar 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.94M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $61.58M | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | $37.43M | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | $42.45M | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | $53.36M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $49.07M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $8.36M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $6.61M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $8.70M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $7.40M | Feb 27, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (3) | Mar 6, 2025 |
| FY2023 | Dec 31, 2023 | 0 | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Feb 24, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (3) | Mar 6, 2025 |
| FY2023 | Dec 31, 2023 | 0 | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Feb 24, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.72M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 37.44M | Mar 12, 2026 |
| FY2024 | Feb 6, 2024 | 3.20M | Mar 6, 2025 |
| FY2023 | Dec 31, 2023 | 14.50M | Feb 1, 2024 |
| FY2023 | Dec 31, 2022 | 14.41M | Feb 1, 2024 |
| FY2022 | Dec 31, 2021 | 14.41M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 9.55M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 1.59M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 773,558 | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | 11.78M | Feb 27, 2019 |